BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 29471517)

  • 1. The role of the ground-glass opacity ratio in resected lung adenocarcinoma.
    Huang TW; Lin KH; Huang HK; Chen YI; Ko KH; Chang CK; Hsu HH; Chang H; Lee SC
    Eur J Cardiothorac Surg; 2018 Aug; 54(2):229-234. PubMed ID: 29471517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Nodule Density in Women With Sublobar Resection for Stage IA Adenocarcinoma.
    Phillips WW; Gill RR; Mazzola E; Armitage JR; de Forcrand C; Colson YL; Gibney BC
    Ann Thorac Surg; 2021 Oct; 112(4):1067-1075. PubMed ID: 33181131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surgical Outcomes of Lobectomy Versus Limited Resection for Clinical Stage I Ground-Glass Opacity Lung Adenocarcinoma 2 Centimeters or Smaller.
    Zhang C; He Z; Cheng J; Cao J; Hu J
    Clin Lung Cancer; 2021 Mar; 22(2):e160-e168. PubMed ID: 33160898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term outcomes of wedge resection for pulmonary ground-glass opacity nodules.
    Cho JH; Choi YS; Kim J; Kim HK; Zo JI; Shim YM
    Ann Thorac Surg; 2015 Jan; 99(1):218-22. PubMed ID: 25440277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival and risk factors for progression after resection of the dominant tumor in multifocal, lepidic-type pulmonary adenocarcinoma.
    Gao RW; Berry MF; Kunder CA; Khuong AA; Wakelee H; Neal JW; Backhus LM; Shrager JB
    J Thorac Cardiovasc Surg; 2017 Dec; 154(6):2092-2099.e2. PubMed ID: 28863952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Presence of Even a Small Ground-Glass Component in Lung Adenocarcinoma Predicts Better Survival.
    Berry MF; Gao R; Kunder CA; Backhus L; Khuong A; Kadoch M; Leung A; Shrager J
    Clin Lung Cancer; 2018 Jan; 19(1):e47-e51. PubMed ID: 28743420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ground-Glass Opacity Is a Strong Prognosticator for Pathologic Stage IA Lung Adenocarcinoma.
    Miyoshi T; Aokage K; Katsumata S; Tane K; Ishii G; Tsuboi M
    Ann Thorac Surg; 2019 Jul; 108(1):249-255. PubMed ID: 30876742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors for lymph node metastasis and surgical methods in patients with early-stage peripheral lung adenocarcinoma presenting as ground glass opacity.
    Wang Y; Jing L; Wang G
    J Cardiothorac Surg; 2020 Aug; 15(1):121. PubMed ID: 32782020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Appropriate sublobar resection choice for ground glass opacity-dominant clinical stage IA lung adenocarcinoma: wedge resection or segmentectomy.
    Tsutani Y; Miyata Y; Nakayama H; Okumura S; Adachi S; Yoshimura M; Okada M
    Chest; 2014 Jan; 145(1):66-71. PubMed ID: 24551879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stepwise flowchart for decision making on sublobar resection through the estimation of spread through air space in early stage lung cancer
    Suh JW; Jeong YH; Cho A; Kim DJ; Chung KY; Shim HS; Lee CY
    Lung Cancer; 2020 Apr; 142():28-33. PubMed ID: 32065918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Proposal for Restaging of Invasive Lung Adenocarcinoma Manifesting as Pure Ground Glass Opacity.
    Mao R; She Y; Zhu E; Chen D; Dai C; Wu C; Xie H; Zhu H; Fei K; Chen C
    Ann Thorac Surg; 2019 May; 107(5):1523-1531. PubMed ID: 30576635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The ground glass opacity component can be eliminated from the T-factor assessment of lung adenocarcinoma.
    Murakawa T; Konoeda C; Ito T; Inoue Y; Sano A; Nagayama K; Nakajima J
    Eur J Cardiothorac Surg; 2013 May; 43(5):925-32. PubMed ID: 23047267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Correlation analysis between imaging features and lymph node metastasis in T1a lung adenocarcinoma].
    Ye B; Feng J; Pan XF; Yang Y; Geng JF; Cao KJ; Zhao H; Hu DZ
    Zhonghua Wai Ke Za Zhi; 2013 Oct; 51(10):904-7. PubMed ID: 24433769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic influence of a ground-glass opacity component in hypermetabolic lung adenocarcinoma.
    Hattori A; Matsunaga T; Fukui M; Takamochi K; Suzuki K
    Eur J Cardiothorac Surg; 2022 Jan; 61(2):249-256. PubMed ID: 34632486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recurrence Patterns and Patient Outcomes in Resected Lung Adenocarcinoma Differ according to Ground-Glass Opacity at CT.
    Park S; Lee SM; Choe J; Choi S; Do KH; Seo JB
    Radiology; 2023 May; 307(3):e222422. PubMed ID: 36943079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ground-glass opacity-featured lung adenocarcinoma has no response to chemotherapy.
    Zhang Y; Deng C; Ma X; Gao Z; Wang S; Zheng Q; Xia G; Wen Z; Han H; Fu F; Liu Q; Hu H; Li Y; Wong KK; Chen H
    J Cancer Res Clin Oncol; 2020 Sep; 146(9):2411-2417. PubMed ID: 32356178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Classification of Multiple Primary Lung Cancers Based on a Ground-Glass Opacity Component.
    Hattori A; Takamochi K; Oh S; Suzuki K
    Ann Thorac Surg; 2020 Feb; 109(2):420-427. PubMed ID: 31593656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Features of Ground Glass Opacity-Dominant Lung Cancer Exceeding 3.0 cm in the Whole Tumor Size.
    Suzuki S; Sakurai H; Yotsukura M; Masai K; Asakura K; Nakagawa K; Motoi N; Watanabe SI
    Ann Thorac Surg; 2018 May; 105(5):1499-1506. PubMed ID: 29427615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective 5-year follow-up study after limited resection for lung cancer with ground-glass opacity.
    Sagawa M; Oizumi H; Suzuki H; Uramoto H; Usuda K; Sakurada A; Chida M; Shiono S; Abe J; Hasumi T; Sato M; Sato N; Shibuya J; Deguchi H; Okada Y
    Eur J Cardiothorac Surg; 2018 Apr; 53(4):849-856. PubMed ID: 29236995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of Pathologic Tumor Invasion and Prognosis for Ground Glass Opacity Featured Lung Adenocarcinoma.
    Ye T; Deng L; Xiang J; Zhang Y; Hu H; Sun Y; Li Y; Shen L; Wang S; Xie L; Chen H
    Ann Thorac Surg; 2018 Dec; 106(6):1682-1690. PubMed ID: 30096292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.